Latest Peptide Research
The most recently published human studies, clinical trials, and review papers on the peptides in our Peptide Database, pulled directly from PubMed (the U.S. National Library of Medicine’s index of biomedical research) and refreshed several times a day.
A new paper is one data point, not a verdict — small, early, or animal-adjacent studies often don’t replicate. Each compound’s database page summarizes where the overall body of evidence actually stands. For informational purposes only; not medical advice.
GLP-1 receptor agonists as potential disease-modifying agents in Parkinson's and Alzheimer's disease: mechanisms, clinical trial evidence, and the neuroprotection horizon
Alsharif M et al. · Frontiers in aging neuroscience · Review
Will GLP-1-based therapies reshape the epidemiology of MASLD? An emerging public health perspective
Pereira ENGDS et al. · Frontiers in endocrinology · Review
Clinical pharmacology of antidiabetic drugs: an update
Wichaiyo S · European journal of clinical pharmacology · Review
Case Report: GADA-positive type 1 diabetes with diabetic ketoacidosis in a young adult with obesity temporally associated with unsupervised tirzepatide use for weight reduction
Lei M et al. · Frontiers in endocrinology · Case Reports
The prodigal peptides
Kalra S et al. · JPMA. The Journal of the Pakistan Medical Association · Review
Rethinking endpoints for anti-obesity pharmacotherapy in patients with hr+ early breast cancer receiving endocrine therapy: from body weight and BMI to body composition
Lampropoulou DI et al. · Expert review of clinical pharmacology · Review
Late Gastric Remnant Necrosis Associated with Paraesophageal Hernia After Roux-en-Y Gastric Bypass
Flores Huidobro Martinez A et al. · CRSLS : MIS case reports from SLS · Case Reports
Availability of age-stratified evidence for GLP1 receptor agonists and SGLT2 inhibitors: an analysis of European public assessment reports with a focus on older patients
Stüdemann S et al. · Frontiers in pharmacology · Review
Next-generation incretin therapeutics for polyendocrine metabolic ovarian syndrome: navigating current pipeline and clinical considerations
Ozgen Saydam B et al. · Expert opinion on pharmacotherapy · Review
[New oral anti-obesity drugs: the future or second choice?]
Hauner H · Innere Medizin (Heidelberg, Germany) · English Abstract
Future directions in obesity pharmacotherapy: Novel targets and pipeline therapies
Mauer Y et al. · Advances in pharmacology (San Diego, Calif.) · Review
Practical use of GLP-1-based medications in obesity clinics
Jethwani PD et al. · Advances in pharmacology (San Diego, Calif.) · Review